by CN Bio. | Sep 8, 2020 | Uncategorised
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define underlying disease mechanisms and screen therapeutic targets. CN Bio, a leading cell culture company, that has developed...
by CN Bio. | Jun 9, 2020 | Uncategorised
Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis Research harnesses CN Bio’s liver-on-chip NASH disease model, to advance development of potential new medicines for liver fibrosis CN Bio, a...
by CN Bio. | Mar 2, 2020 | Press releases
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by existing investor CN Innovations Headquarters relocated to larger premises in Cambridge Science Park, a leading UK life sciences...
